Based on a deep molecular characterisation of individual tumours and patients
Based on a deep molecular characterisation of individual tumours and patients
Establishment and use of digital medicine approaches to model effects and side effects of all therapy options
Transformation in current health care practice across Europe, necessitating engagement of all stakeholders
ITFoC will establish a standardised and well-validated approach for virtual patient modelling in oncology, through comparative analysis of computational model approaches for predicting patient response to treatment based on molecular data (e.g. exome/transcriptome/metabolome) from individual patients and tumours. Existing and newly generated large scale molecular and clinical datasets on (triple negative) breast cancer patients from across Europe, as well as ongoing data standard initiatives, will be leveraged to provide standardised and validated datasets, accessible via a common database.
Collaborative ties with relevant scientists, clinicians, interested individuals as well as existing initiatives can be established and bolstered to define the roadmap towards implementation of optimal digital medicine driven cancer care in European healthcare systems.
Over the last decades we have made major progress in diagnosing and treating cancer, however, these diseases remain one of the leading causes of morbidity and mortality worldwide, responsible for millions of death each year. A ‘moonshot to cure cancer’ is being called for which could translate this enormous progress into tangible outcomes for patients. To be able to provide ‘the right drug for every patient’, we propose here to develop demonstrators, based on a deep molecular characterisation of tumour and patient as input to virtual patient models on the individual patient in silico. ITFoC Consortium include a number of 17 partners from 6 European countries. See below.